Ascites relative enhancement during hepatobiliary phase after Gd-BOPTA administration: a new promising tool for characterising abdominal free fluid of unknown origin.
Ascites
Gadobenate dimeglumine
Liver
Magnetic resonance imaging
Peritoneal neoplasms
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
22
08
2018
accepted:
29
11
2018
revised:
10
11
2018
pubmed:
16
1
2019
medline:
6
8
2019
entrez:
16
1
2019
Statut:
ppublish
Résumé
To correlate the degree of ascites enhancement during hepatobiliary phase after gadobenate dimeglumine (Gd-BOPTA) administration with ascites aetiology. IRB-approved retrospective study, need for informed consent was waived. We included 74 consecutive ascitic patients who underwent Gd-BOPTA-enhanced liver MRI including hepatobiliary phase (HBP) images between January 2014 and December 2017. Ascites appearance on unenhanced and HBP images was classified as hypo-, iso- or hyperintense in comparison to paraspinal muscles. Ascites signal intensity on unenhanced and HBP images was measured using round ROIs and was normalised to paraspinal muscles (NSI). Normalised relative enhancement (NRE) between native phase and HBP was calculated. The results were related to ascites aetiology using Wilcoxon and Mann-Whitney tests. On native images, ascites appeared hypointense in 95.9% of the cases and isointense in 4.1%, whereas on HBP images, it appeared hyperintense in 59.4% of the cases, isointense in 36.5% and hypointense in 4.1%. Mean ascites NSI was 0.52 on unenhanced images and 1.50 on HBP ones (p < 0.0001). Mean ascites NRE was 201 ± 133%. Ascites of non-malignant aetiology showed mean NRE of 210 ± 134%, whereas malignant ascites showed mean NRE of 92 ± 20% (p = 0.001). ROC analysis showed that a NRE < 112.5% correlates with malignant aetiology with 100% sensitivity and 83.4% specificity (LR = 5.667). NRE did not show any significant correlation with ascites thickness, eGFR and time interval between contrast administration and HBP acquisition (p > 0.05). Ascites NRE in HBP after Gd-BOPTA administration is significantly lower in patients with ascites secondary to peritoneal carcinomatosis than in patients with non-malignant ascites. • Ascites enhancement in the hepatobiliary phase after Gd-BOPTA administration may determine false positive findings when looking for biliary leaks. • Ascites enhancement in the hepatobiliary phase after Gd-BOPTA administration is lower in patients with peritoneal carcinomatosis than in patients with portal hypertension or congestive heart failure. • None of the patients with peritoneal carcinomatosis showed an ascites enhancement of more than 112% as compared with unenhanced images.
Identifiants
pubmed: 30643946
doi: 10.1007/s00330-018-5932-y
pii: 10.1007/s00330-018-5932-y
doi:
Substances chimiques
Contrast Media
0
Organometallic Compounds
0
gadobenic acid
15G12L5X8K
Meglumine
6HG8UB2MUY
Types de publication
Journal Article
Langues
eng
Pagination
2830-2836Références
Clin Liver Dis. 2000 May;4(2):447-65
pubmed: 11232200
Ann Oncol. 2001 Oct;12(10):1353-7
pubmed: 11762804
Med Clin North Am. 2009 Jul;93(4):801-17, vii
pubmed: 19577115
AJR Am J Roentgenol. 2009 Aug;193(2):461-70
pubmed: 19620444
AJR Am J Roentgenol. 2009 Sep;193(3):732-7
pubmed: 19696286
Radiographics. 2009 Oct;29(6):1725-48
pubmed: 19959518
Eur J Radiol. 2011 Nov;80(2):224-8
pubmed: 20598823
J Magn Reson Imaging. 2012 Mar;35(3):492-511
pubmed: 22334493
Diagn Interv Imaging. 2012 May;93(5):365-70
pubmed: 22542208
Diagn Interv Imaging. 2013 Apr;94(4):443-52
pubmed: 23433543
Radiographics. 2014 May-Jun;34(3):613-23
pubmed: 24819784
Br J Radiol. 2015 Apr;88(1048):20140526
pubmed: 25651409
Radiol Bras. 2014 Sep-Oct;47(5):301-9
pubmed: 25741105
J Clin Transl Hepatol. 2014 Mar;2(1):58-64
pubmed: 26357618
J Gastrointest Cancer. 2017 Mar;48(1):50-57
pubmed: 27614744
Can Assoc Radiol J. 2017 Aug;68(3):293-307
pubmed: 28583364
Eur Radiol. 2018 Jul;28(7):3020-3031
pubmed: 29374320
AJR Am J Roentgenol. 1993 Oct;161(4):787-90
pubmed: 8372759
Abdom Imaging. 1996 Jan-Feb;21(1):67-8
pubmed: 8672977
Invest Radiol. 1996 Feb;31(2):80-3
pubmed: 8750442